Clinical Trial Update: Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update reports results for dendritic cell therapy combined with pembrolizumab in metastatic or unresectable melanoma; the study was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dendritic cell therapy
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Mayo Clinic | Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-06-12